
Wells Fargo Taps Annexon as Top Biotech Pick on Pipeline Potential
Wells Fargo has named Annexon its top biotechnology stock, citing a significant upside potential of 7-8 times in its bull case. The firm's optimism is based on upcoming catalysts, including Phase 3 data for its geographic atrophy drug and a regulatory filing for its Guillain-Barré syndrome treatment.







